SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 16:03:27 23/05/2024 BST | ||
| 5.09 EUR | +1.39% |
|
| Current month | +2.66% | ||
| 1 month | +13.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 5.09 | +1.39% |
| 22/05/24 | 5.02 | 0.00% |
| 21/05/24 | 5.02 | +2.45% |
| 20/05/24 | 4.9 | +0.62% |
| 17/05/24 | 4.87 | +0.41% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 04:03 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VV9EYB |
| ISIN | DE000VV9EYB8 |
| Date issued | 09/11/2022 |
| Strike | 96.96 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.91 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.09 € |
|---|---|
| Lowest since issue | 1.63 € |
| Spread | 0.01 € |
| Spread % | 0.20% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.34
USD
Average target price
53.19
USD
Spread / Average Target
+25.64%
- Stock Market
- Certificates
- Certificat
